請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52190
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳達仁 | |
dc.contributor.author | Po-Hui Chiang | en |
dc.contributor.author | 江博暉 | zh_TW |
dc.date.accessioned | 2021-06-15T16:09:16Z | - |
dc.date.available | 2025-08-17 | |
dc.date.copyright | 2015-08-19 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-19 | |
dc.identifier.citation | Data from the Beurau of National Health Taiwan 2008
2. Yancik, R.: Population aging and cancer: a cross-national concern. Cancer J, 11: 437, 2005 3. Quinn, M., Babb, P.: Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int, 90: 162, 2002 4. Wilt, T. J., Brawer, M. K., Jones, K. M. et al.: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med, 367: 203, 2012 5. Bellardita, L., Rancati, T., Alvisi, M. F. et al.: Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol, 64: 30, 2013 6. Ficarra, V., Novara, G., Rosen, R.C. et al.: Systematic review and meta-analysis of studies reportig urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol, 62:405, 2012 7. Ficarra, V., Novara, G., Ahlering, T.E. et al.: Systematic review and meta-analysis of studies reportig potency rates after after robot-assisted radical prostatectomy. Eur Urol, 62:418, 2012 8. Robinson, J.W., Moritz, S., Fung, T.: Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys, 54:1063, 2002 9. Thuroff, S., Chaussy, C.: High-intensity focused ultrasound for prostate cancer. In: Li-Ming Su and Stephen C Young (eds). Early Diagnosis and Treatment of Cancer: Prostate Cancer 2008, Saunders E lsevier Chapter 9:177-192 10. Bianco, F. J., Jr., Scardino, P. T., Eastham, J. A.: Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ('trifecta'). Urology, 66: 83, 2005 11. Polascik, T. J., Nosnik, I., Mayes, J. M. et al.: Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology, 70: 117, 2007 12. Uchida, T., Tomonaga, T., Kim, H. et al.: Improved outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer. J Urol, 193: 103, 2015 13. Ganzer, R., Fritsche, H. M., Brandtner, A. et al.: Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. BJU Int, 112: 322, 2013 14. Vallancien, G., Prapotnich, D., Cathelineau, X. et al.: Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol, 171: 2265, 2004 15. Jones, J. S., Rewcastle, J. C., Donnelly, B. J. et al.: Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol, 180: 554, 2008 16. Thuroff, S., Chaussy, C.: Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years. J Urol, 190: 702, 2013 17. Crouzet, S., Chapelon, J. Y., Rouviere, O. et al.: Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol, 65: 907, 2014 18. Marberger, M., Carroll, P. R., Zelefsky, M. J. et al.: New treatments for localized prostate cancer. Urology, 72: S36, 2008 19. Robinson, J. W., Donnelly, B. J., Saliken, J. C. et al.: Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology, 60: 12, 2002 20. Onik, G., Narayan, P., Vaughan, D. et al.: Focal 'nerve-sparing' cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology, 60: 109, 2002 21. Mearini, L., Nunzi, E., Giovannozzi, S. et al.: Urodynamic evaluation after high-intensity focused ultrasound for patients with prostate cancer. Prostate Cancer, 2014: 462153, 2014 22. Inoue, Y., Goto, K., Hayashi, T. et al.: Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer. Int J Urol, 18: 358, 2011 23. Poissonnier, L., Chapelon, J. Y., Rouviere, O. et al.: Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol, 51: 381, 2007 24. Ahmed, H. U., Moore, C., Emberton, M.: Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol, 18: 219, 2009 25. Li, L. Y., Lin, Z., Yang, M. et al.: Comparison of penile size and erectile function after high-intensity focused ultrasound and targeted cryoablation for localized prostate cancer: a prospective pilot study. J Sex Med, 7: 3135, 2010 26. Shoji, S., Nakano, M., Nagata, Y. et al.: Quality of life following high-intensity focused ultrasound for the treatment of localized prostate cancer: a prospective study. Int J Urol, 17: 715, 2010 27. Caso, J. R., Tsivian, M., Mouraviev, V. et al.: Complications and postoperative events after cryosurgery for prostate cancer. BJU Int, 109: 840, 2012 28. Sumitomo, M., Asakuma, J., Sato, A. et al.: Transurethral resection of the prostate immediately after high-intensity focused ultrasound treatment for prostate cancer. Int J Urol, 17: 924, 2010 29. Chaussy, C., Thuroff, S.: The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep, 4: 248, 2003 30. Shoji, S., Uchida, T., Nakamoto, M. et al.: Prostate swelling and shift during high intensity focused ultrasound: implication for targeted focal therapy. J Urol, 190: 1224, 2013 31. Thuroff, S., Chaussy, C., Vallancien, G. et al.: High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol, 17: 673, 2003 32. Limani, K., Aoun, F., Holz, S. et al.: Single high intensity focused ultrasound session as a whole gland primary treatment for clinically localized prostate cancer: 10-year outcomes. Prostate Cancer, 2014: 186782, 2014 33. Elliott, S. P., Meng, M. V., Elkin, E. P. et al.: Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol, 178: 529, 2007 34. Mottet, N., Bellmunt, J. , van den Bergh, R.C.N. et al. : Guidelines on Prostate Cancer. 2014 35. Blana, A., Rogenhofer, S., Ganzer, R. et al.: Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology, 72: 1329, 2008 36. Lee, H.M. et al. : High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 9: 439-443, 2006 37. Poissonnier, L. et al. : Control of prostate cancer by transrectal HIFU in 227 patients. Eur. Urol. 51:381-387, 2007 38. Blana, A. et al. :First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur. Urol. 53(6):1194-1201, 2008 39. Blana, A. et al. :Eight years`experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 72(6):1329-1333, 2008 40. Ganzer, R. et al. :PSA nadir is a significant predictor of treatment failure after high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. Eur. Urol. 53:547-553, 2008 41. Crouzet, S. et al. :Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 58 (4): 559–566, 2010 42. Crouzet, S. et al. : Locally recurrent prostate cancer after initial radiation therapy: early salvage high intensity focuse ultrasound improves oncologic outcomes. Radiotherapy and Oncology Vol 125(2); p. 198-202, 2012 43. Argawal et al.: Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes. CANCER; Vol 112 (2); p-307-314, 2008 44. Thuroff, S., Chaussy, C.: Evolution and outcomes of 3 MHz High intensity focused ultrasound therapy for localized prostate cancer over 15 years, The Journal of UrologyR. 190(2):702-710, 2013 45. Chaussy, C. et al. : Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J. Endourol. 15: 437-440, 2001 46. Chaussy, C., Thuroff, S. :The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 4: 248–252, 2003 47. Ficarra, V. et al. :Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int. 98: 1193-1198, 2006 48. Muto, S. et al.:Focal therapy with high intensity focused ultrasound in the treatment of localized prostate cancer. Jpn. J. Clin. Oncol. 38(3): 192-199, 2008 49. Vallancien, G. et al. :Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 171 (Pt 1): 2265–2267, 2004 50. Gelet, A. et al. :Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urol 63: 625–629, 2004 51. Chaussy, C.G., Thuroff, S. :Robot-assisted high-intensity focused ultrasound in Prostate Cancer. J Endourol. 245:843-847, 2010 52. Chaussy, C., Thuroff, S. :Local recurrence of prostate cancer after curative therapy. HIFU (Ablatherm) as a treatment option. Urologe A, 45 (10):1271-1275, 2006 53. Baumunk, D., Cash H Ebbing, J., Porsch, M. et al. :HIFU in Salvage Treatment of Patients with Prostate Cancer after Primary External Radiation Therapy-status 2012. Akt Urol, 2012 54. Murat, F.J., Poissonnier, L., Rabilloud, M. et al. :Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur. Urol. 55(3): 640-647, 2009 55. Berge, V., Baco, E. Karlsen, S. J. : A prospective study of salvage high-intensity focused ultrasound for locally radiorecurrent prostate cancer: early results. Scandinavian Journal of Urology and Nephrology; Vol 44(4); p 223-227, 2010 56. Thuroff, S., Chaussy, C. : High-intensity focused ultrasound: complications and adverse events. Mol Urol 4: 183-187, 2000 57. Thuroff, S., Chaussy, C. : High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 17: 673-677, 2003 58. Hayashi, M., Shinmei, S., Asano, K. :Transrectal high-intensity focused ultrasound for treatment for patients with biochemical failure after radical prostatectomy. Int. J. Urol. 14:1048-1050, 2007 59. Riviere, J., Bernhard, J. C., Robert, G., et al. : Salvage Radiotherapy after high-intensity focussed ultrasound for recurrent localized prostate cancer. European Urology Vol. 58 (4) :567-573, 2010 60. Kiel, H.J., Thuroff S. :Induction of systemic PSA-specific T cell response in prostate cancer patients after treatment with high intensive focused ultrasound. 23th World Congress of Endourology & SWL. August 23–26, 2005. Amsterdam, MP01-11 61. Lu, P., Zhu, X. Q., Xu, Z.L. et al. :Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. Surgery 145 (3): 286-293, 2009 62. Wu, F., Wang, Z.B., Cao, Y.D. et al. : Expression of tumor antigens and heat-shock protein 70 in breast cancer cells after high-intensity focused ultrasound ablation. Ann. Surg. Oncol. 14(3): 1237-1242, 2007 63. Uchida, T., Tomonaga, T., Kim, H. et al.: Improved outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer. J Urol, 193(1):103, 2015 64. Liu, Y.Y., Chiang, P.H., Chuang, Y.C. et al.: Predictors of PSA biochemical recurrence in patients undergoing primary whole gland prostate cryoablation. Ann Surg Oncol. 2014 65. Luo, H.L., Fang, F.M., Chiang, P.H.: Can High-Dose-Rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate? Int Urol Nephrol. 45(1):113-9. 2013 66. Fang, F.M., Wang, Y.M., Chiang, P.H.: Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Jpn J Clin oncol. 38(7):474-9. 2008 67. Chinag, P.H., Fang, F.M., Wang, C.J.: High-dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation. Int J Urol. 11(3);152-8. 2004 68. Kim, W.C., Mauborgne, R.: Blue Ocean Strategy: How to Creat Uncontested Market Space and Make the Competition Irrelevent 2005 天下遠見 69. Johnson, M.:Seizing the white space-business model innovation for growth and renewal 2013 天下文化 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52190 | - |
dc.description.abstract | 攝護腺癌無論在發生率及死亡率在台灣都逐年增加。而早期攝護腺癌也約佔了所有病人的一半。早期攝護腺癌的治療傳統以手術切除(其中又包含了恥骨後攝護腺根除手術,腹腔鏡攝護腺根除手術及機器手臂腹腔鏡攝護腺根除手術)及放射線治療為主。由於攝護腺癌的發生集中在70至79歲的老年人,傳統治療往往造成過度治療及帶來尿失禁及性功能障礙等嚴重影響生活品質的後遺症。而氬氦刀冷凍治療及機器手臂海福刀則是屬微創手術。但由於很少機構同時可執行這些治療,並進行比較。在本研究中利用2008年以來,接受過早期攝護腺癌治療的病患,比較其腫瘤控制,併發症,並評估其國際勃起功能指標,國際攝護腺症狀量表,及生活品質量表,來評估以期找出早期攝護腺癌的最佳化治療方式。
海福刀是利用高強度超音波聚焦至病灶區以超音波脈衝波及所產生的高溫來破壞癌組織。作法是以超音波探頭置入直腸以電腦機器定位作微創治療。與手術切除,放射線治療及氬氦刀冷凍治療比較起來,在低危險及中危險群,腫瘤控制是相似的,但在高危險群中放射線的腫瘤控制則略遜一籌。在國際勃起功能指標,國際攝護腺症狀量表,及生活品質量表的評估則顯示海福刀在性功能的保留,術後排尿功能的改善及生活品質的維持表現最佳。 由於海福刀是法國公司開發,迄今尚未取得美國食品葯物管理局的通過,並在攝護腺癌病人數最多的美國上市。加上泌尿科醫師普遍對超音波的操作不熟悉,而放射影像醫師則熱衷於高利潤的放射線治療,使得海福刀一直未能普及。本研究以SWOT分析並提出行銷策略改善方式。 而高頻聚焦超音波這項新科技未來也可能運用在治療肝腫瘤,腦腫瘤及腎腫瘤。現代的醫療人員如何掌握新科技,改變人類的生活,創造藍海策略的藍天思考模式是值得探討的。 | zh_TW |
dc.description.abstract | The incidence and mortality rate of prostate cancer are increasing in Taiwan. Nearly half of prostate cancer patients are classified into localized prostate cancer. The classical treatments for localized prostate cancer are surgeries including of retropubic radical prostatectomy, laparoscopic radical prostatectomy and robotic assisted laparoscopic radical prostatectomy) and radiotherapy. The age of most of the prostate cancer patients are between 70 and 79 years old. The traditional treatments often result in overtreatment and seriously adverse events such as incontinence and erectile dysfunction etc. Cryoablation and high intensity focused ultrasound (HIFU) are minimally invasive treatments for localized prostate cancer. However, it is very difficult to compare these treatment modalities in the same institute. In this study patients treated with these treatment modalities were collected for analysis of cancer control and adverse events to find the optimization of treatment for localized prostate cancer since 2008. The international index of erectile function (IIEF), international prostate symptom score (IPSS) and questionnaire for quality of life (QoL) were also used to evaluate the postoperative erectile function, urinary function and quality of life.
The mechanism of HIFU is that focused transducer emits bursts of convergent high intensity ultrasound waves with creation of an intense temperature rise, which destroys the cells located in the target area without damage to the surround tissue. In comparison with surgery and cryoablation the cancer control is similar in low and intermediate risk groups. On the contrary, radiotherapy is inferior to other three treatment modalities in high risk group. The patients of HIFU had significantly better IIEF, IPSS and QoL in comparison with surgery, radiotherapy and cryoablation. The intracorporeal HIFU device was developed by EDAP TMS SA and is not approved by the US Food Drug Administration. The American prostate cancer market is the largest in the world. However, the urologists are not familiar with ultrasound and the radiologists are enthusiastic with high profit radiotherapy. These factors make HIFU not popular in the world. SWOT analysis and marketing strategy are proposed in this study. HIFU may be used in the treatment of renal tumor, liver tumor and brain tumor. The physicians or surgeons in the modern era should have the mind of blue sky thinking to create medicine model innovation blue ocean strategy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T16:09:16Z (GMT). No. of bitstreams: 1 ntu-104-P02546015-1.pdf: 2794374 bytes, checksum: a7aff879256f7821849c94670a8dc7ed (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | Abstract i
摘要 iii Content iv Legend vi Chapter 1 Introduction 1 1.1 Background of study 1 1.2 Complications and functional outcome of radical prostatectomy 2 1.3 Complications and functional outcome of radiotherapy 2 1.4 Conclusion 2 Chapter 2 Comparisons of oncological and functional outcomes between primary whole-gland cryoablation and high-intensity focused ultrasound for localized prostate cancer 4 2.1 Introduction of HIFU 4 2.2 Material and methods 6 2.3 Results 7 2.4 Discussion 9 2.5 Conclusion 15 Chapter 3 Miscellaneous applications of HIFU in the different stage of prostate cancer with literature review and my clinical experiences 26 3.1 HIFU in localized prostate cancer (T1-2) 26 3.2 Incidental prostate cancer 28 3.3 Focal HIFU in primary prostate cancer 29 3.4 Focal salvage HIFU in irradiated prostate cancer 31 3.5 Side effects 31 3.6 Salvage HIFU after radiation 33 3.7 Salvage HIFU after surgery or surgery and radiation 34 3.8 HIFU retreatment 35 3.9 HIFU locally advanced or castration resistant prostate cancer 35 3.10 Salvage radiation after failed repetitive HIFU 36 3.11 HIFU caused immuinduction 36 3.12 Personal experiences 36 Chapter 4 SWOT analysis for HIFU procedure and EDAP TMS 45 4.1 Introduction 45 4.2 SWOT analysis of HIFU procedure 45 4.3 SWOT analysis of EDAP TMS 47 4.4 PEST analysis of HIFU procedure and EDAP TMS 50 Chapter 5 The blue sky thinking of HIFU 53 References 56 | |
dc.language.iso | en | |
dc.title | 局限性攝護腺癌治療之SWOT分析-以高頻聚焦超音波為例 | zh_TW |
dc.title | SWOT Analysis for Treatments of Localized Prostate Cancer- Using High-Intensity Focused Ultrasound as an Example | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 周雍強,吳政鴻 | |
dc.subject.keyword | 攝護腺癌,海福刀,高強度聚焦超音波,氬氦刀冷凍治療,SWOT,行銷策略, | zh_TW |
dc.subject.keyword | Prostate cancer,HIFU,High intensity focused ultrasound,Cryoablation,SWOT,Marketing strategy, | en |
dc.relation.page | 65 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-19 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 工業工程學研究所 | zh_TW |
顯示於系所單位: | 工業工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 2.73 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。